AI Stock Analysis: Is CLDI a Buy?

July 19, 7:13 am

Calidi Biotherapeutics is a cutting-edge biopharmaceutical company that focuses on innovative therapies in oncology and other advanced areas of medicine. Their primary aim is to leverage advanced biotechnological platforms to develop new treatments that can make a significant difference in the medical field. Despite having groundbreaking potential, the company’s recent performance must be scrutinized to gauge its investment viability.

Price & AI Score for CLDI.

Fundamental Analysis

A fundamental review of Calidi Biotherapeutics raises several points for consideration. The company reported a revenue of 0 for the last quarter, plunging by 100.00% compared to both the previous quarter and the same quarter last year. This significant drop suggests potential operational or market challenges.

On a more positive note, the net income for the last quarter was $7.2M. This shows a notable increase of 12.20% from the previous quarter, suggesting improved profitability. However, it should be noted that this figure represents an 11.81% decline compared to the same quarter last year, indicating potential issues in long-term growth stability.

The EBITDA remained at 0 both in the last quarter and the same quarter last year, showing consistency in earnings before interest, tax, depreciation, and amortization. While this might initially seem neutral, the flat trend necessitates further investigation into the company’s cost management and operational efficiency.

Technical Analysis

The stock price of Calidi Biotherapeutics is currently $1.76, impressively up by a staggering 780.00% compared to a month ago, signaling a sharp short-term upward trend. However, compared to a year ago, this price represents a decline of 83.29%, which could signify larger, more systemic issues within the company or its market.

The technical indicators are mixed. The current Simple Moving Average for 10 days (SMA10) is 0.96, up from a previous SMA10 of 0.80, indicating a potential bullish trend. However, the Relative Strength Index (RSI) stands at 50, which suggests a neutral position, so investors should await further signals before making decisions.

Alternative Data Analysis

Alternative data provides additional insight into the company's current status. Starting with job postings and employee sentiment, Calidi Biotherapeutics has 0 open positions, a number that has been stable over recent months, indicating no immediate plans for expansion or contraction.

In terms of customer acquisition, the company has approximately 3,000 website visitors, a decrease of 25% in the last couple of months. This decline is concerning as it may indicate reduced interest or market engagement.

However, social media metrics offer a glimmer of optimism. The number of followers on their Twitter page has increased by 40%, now standing at 56 followers, suggesting growing interest and engagement.

Impressively, the AltIndex's AI score for Calidi Biotherapeutics is 61, which is a buy signal. This score aggregates various factors, including fundamentals, technicals, and alternative data, to predict future stock performance.

Conclusion and Recommendation

To encapsulate, Calidi Biotherapeutics presents a mixed bag of signals for investors. Their lack of revenue growth is alarming, yet their increasing net income and stable EBITDA offer some reassurance. Technically, the stock shows a bullish short-term trend, though long-term issues persist.

Despite a decline in web visitors, a rise in social media engagement and a positive AI score suggest potential for future growth. Given these mixed indicators, a moderate investment stance is advisable, with a ‘Buy’ rating but caution about market volatility and long-term performance uncertainties.

Disclaimer: This article, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current. Visit CLDI AI Stock Analysis for a more up-to-date analysis.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.